127.50 -0.30 (-0.23%)
Pre-market: 7:11AM EDT
|Bid||127.08 x 800|
|Ask||128.17 x 1100|
|Day's range||127.17 - 129.05|
|52-week range||118.62 - 148.32|
|PE ratio (TTM)||282.74|
|Earnings date||16 Oct 2018|
|Forward dividend & yield||3.60 (2.86%)|
|1y target est||143.45|
The FDA approves Johnson and Johnson's (JNJ) darunavir-based single-tablet regimen, Symtuza, for the treatment of type 1 HIV-1 in treatment-naive and certain virologically suppressed adults.
Investors should closely watch the movement of the Johnson & Johnson and keep a close eye on ETFs having double-digit allocation to this diversified drug maker.
A Missouri jury asked Johnson & Johnson (JNJ) to pay $4.69 billion in damages to 22 women and their families, who alleged that the company's baby powder contained asbestos that caused them to develop ovarian cancer.
SINGAPORE (AP) — Asian markets climbed higher on Wednesday as a sweep of positive news from Wall Street and beyond boosted confidence in the U.S. economy.
Shares of Novartis (NVS) added just 0.14% during regular hours Tuesday, the last day of trading before the pharma giant releases its latest quarterly earnings report. Here's what to expect tomorrow morning.
On a day stocks climbed following optimistic comments by the chairman of the Federal Reserve, Netflix reported disappointing subscriber additions, and Johnson & Johnson rose on strong pharmaceuticals sales.
Stocks notched another day of gains on Tuesday, on a day when there was little in the way of market-moving news. The Dow Jones Industrial Average gained 55.53 points, or 0.22%, to 25,119.89, while the S&P 500 is up 11.12 points, or 0.40%, to 2809.55 and the Nasdaq Composite added 49.40 points, or 0.63%, to 7855.12. Part of it may have been a "no news is good news," sort of mentality, as Federal Reserve Chief Jerome Powell's dry testimony before the Senate Banking Committee seemed to indicate that the Central Bank was committed to staying the course and markets largely shrugged off earnings reports on a relatively quiet day.
Stocks that moved substantially or traded heavily Tuesday: Netflix Inc., down $21 to $379.48 The streaming video company's second-quarter subscriber gains were weaker than analysts expected. Johnson & ...
Johnson & Johnson's (JNJ) phase III CREDENCE study evaluating the efficacy and safety of its diabetes drug Invokana is being stopped early based on positive pre-specified efficacy data.
A unit of U.S. health-care giant Johnson & Johnson has agreed to sell global rights to a treatment for a rare blood disorder to Britain’s Eusa Pharma. Eusa Pharma is buying the rights to the drug Sylvant from Janssen Sciences Ireland UC for $115 million in cash, the Hemel Hempstead, England-based company said Wednesday, confirming a Bloomberg report. Eusa Pharma is working to focus its operations fully on treatments for oncology and rare diseases.
Shares of Johnson & Johnson (JNJ) are higher on Tuesday on the heels of the drug and personal products maker's second-quarter earnings, and although they're on track for their best day since early 2016, the stock is still lodged in the red for the year to date. The division saw sales jump 20%, helping to offset the performance of J&J’s consumer segment, which saw U.S. revenue decline 0.7%. J&J stock is on track to log its biggest percentage increase since the start of 2016. It's a far cry from last week, when a jury awarded $4.69 billion in damages to cancer patients who used J&J's talc products, sending the shares lower.
Fueled by a 20 percent sales jump in its prescription drugs business, Johnson & Johnson posted a 3 percent increase in second-quarter profit. J&J's prescription medicine business, which had lagged its medical device business until a couple years ago, accounted for half its $20.83 billion in total revenue.
J&J (JNJ) beats estimates for both earnings and sales in the second quarter of 2018. However, it narrows its full year sales forecast due to currency factors.
Goldman Sachs (GS) CEO and Chairman Lloyd Blankfein announced his replacement this morning as the company he's run for the past 12 years easily beat earnings and revenue projections in its Q2 report.
Netflix led tech stocks lower early Tuesday as Johnson & Johnson, Goldman Sachs and UnitedHealth Group reported and markets looked toward Senate testimony from Fed Chief Powell.
A Missouri jury asked Johnson & Johnson (JNJ) to pay $4.69 billion in damages to 22 women and their families who alleged that the company's baby powder contained asbestos that caused them to develop ovarian cancer.
The Dow Jones Industrial Average is edging lower this morning as UnitedHealth Group (UNH) slips on earnings. If so it will have to come from something we haven't seen yet, like Fed Chairman Jerome Powell's testimony before Congress. As for Powell, Nick Colas, co-founder of DataTrek Research, contends that he will want to convince the market that the Fed will raise rates two more times this year, a one-hike-per-quarter pace.
J&J (JNJ) beats estimates for both earnings and sales in the second quarter of 2018. However, it tightens its previously issued earnings guidance for 2018 while lowering its sales range.